Wedmont Private Capital Sells 934 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wedmont Private Capital lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 54.7% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 773 shares of the biopharmaceutical company's stock after selling 934 shares during the quarter. Wedmont Private Capital's holdings in Regeneron Pharmaceuticals were worth $490,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in REGN. Capital International Investors lifted its position in Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after buying an additional 155,369 shares during the period. Dodge & Cox lifted its position in shares of Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock valued at $1,653,543,000 after buying an additional 9,381 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after acquiring an additional 810,144 shares during the period. Finally, Franklin Resources Inc. grew its stake in shares of Regeneron Pharmaceuticals by 7.9% during the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after acquiring an additional 149,124 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on REGN. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price on the stock. The Goldman Sachs Group dropped their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Guggenheim reissued a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Finally, Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating on the stock in a report on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $836.48.

Regeneron Pharmaceuticals Trading Up 0.2%

REGN traded up $1.26 during trading on Thursday, reaching $519.86. The company had a trading volume of 247,800 shares, compared to its average volume of 870,685. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The business has a 50 day simple moving average of $564.76 and a 200-day simple moving average of $653.10. The stock has a market cap of $56.13 billion, a P/E ratio of 13.58, a PEG ratio of 2.34 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the business posted $9.55 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.